[Show abstract][Hide abstract] ABSTRACT: An increase in the antibiotic resistance among members of the Enterobacteriaceae family has been observed worldwide. Multidrug-resistant Gram-negative rods are increasingly reported. The treatment of infections caused by Escherichia coli and other Enterobacteriaceae has become an important clinical problem associated with reduced therapeutic possibilities. Antimicrobial carbapenems are considered the last line of defense against multidrug-resistant Gram-negative bacteria. Unfortunately, an increase of carbapenem resistance due to the production of Klebsiella pneumoniae carbapenemase (KPC) enzymes has been observed. In this study we describe the ability of E. coli to produce carbapenemase enzymes based on the results of the combination disc assay with boronic acid performed according to guidelines established by the European Community on Antimicrobial Susceptibility Testing (EUCAST) and the biochemical Carba NP test. Moreover, we evaluated the presence of genes responsible for the production of carbapenemases (íµí±íµí±íµí± KPC , íµí±íµí±íµí± VIM , íµí±íµí±íµí± IMP , íµí±íµí±íµí± OXA-48) and genes encoding other íµí»½-lactamases (íµí±íµí±íµí± SHV , íµí±íµí±íµí± TEM , íµí±íµí±íµí± CTX-M) among E. coli isolate. The tested isolate of E. coli that possessed the íµí±íµí±íµí± KPC-3 and íµí±íµí±íµí± TEM-34 genes was identified. The tested strain exhibited susceptibility to colistin (0.38 íµí¼g/mL) and tigecycline (1 íµí¼g/mL). This is the first detection of íµí±íµí±íµí± KPC-3 in an E. coli ST479 in Poland.
BioMed Research International 11/2014; · 2.71 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Bacteria belonging to the Enterobacteriaceae family that produce extended-spectrum β-lactamase (ESBL) enzymes are important pathogens of infections. Increasing numbers of ESBL-producing bacterial strains exhibiting multidrug resistance have been observed. The aim of the study was to evaluate the prevalence of , , and genes among ESBL-producing Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis strains and to examine susceptibility to antibiotics of tested strains. In our study, thirty-six of the tested strains exhibited genes , , , and . Moreover, twelve ESBL-positive strains harbored genes , , , and , and the presence of a gene in twenty-five ESBL-positive strains was revealed. Among K. pneumoniae the multiple ESBL genotype composed of , and genes encoding particular ESBL variants was observed. Analysis of bacterial susceptibility to antibiotics revealed that, among β-lactam antibiotics, the most effective against E. coli strains was meropenem (100%), whereas K. pneumoniae were completely susceptible to ertapenem and meropenem (100%), and P. mirabilis strains were susceptible to ertapenem (91.7%). Moreover, among non-β-lactam antibiotics, gentamicin showed the highest activity to E. coli (91.7%) and ciprofloxacin the highest to K. pneumoniae (83.3%). P. mirabilis revealed the highest susceptibility to amikacin (66.7%).
The Journal of Antibiotics 01/2014; · 2.04 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: The aim of this study was to investigate the prevalence of the aacA4 gene in a population of multidrug resistant strains of P. aeruginosa isolated from bronchial secretions obtained from the Intensive Therapy Unit (ITU). Twelve MDR isolates were tested for antibiotic susceptibility and the presence of the aacA4 gene. In this study, 58.3% of the strains contained (6')-Ib' aminoglycoside acetyltransferase gene. All of the studied strains (aacA4-positive and aacA4-negative) were susceptible only to colistine (100%). Among other antibiotics, the lowest resistance rates were those shown against ceftazidime (14.3% to 20%) and imipenem (28.6% to 40%). Our studies frequently revealed the presence of the aacA4 gene as a factor responsible for resistance; it is probable that other mechanisms of resistance to aminoglycoside antibiotics also occurred.
Folia Histochemica et Cytobiologica 07/2012; 50(2):322-4. · 1.10 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Antimicrobial resistance due to the continuous selective pressure from widespread use of antimicrobials in humans, animals and agriculture has been a growing problem for last decades. KPC beta-lactamases hydrolyzed beta-lactams of all classes. Especially, carbapenem antibiotics are hydrolyzed more efficiency than other beta-lactam antibiotics. The KPC enzymes are found most often in Enterobacteriaceae. Recently, these enzymes have been found in isolates of Pseudomonas aeruginosa and Acinetobacter spp. The observations of blaKPC genes isolated from different species in other countries indicate that these genes from common but unknown ancestor may have been mobilized in these areas or that blaKPC-carrying bacteria may have been passively by many vectors. The emergence of carbapenem resistance in Gram-negative bacteria is worrisome because the carbapenem resistance often may be associated with resistance to many beta-lactam and non-beta-lactam antibiotics. Treatment of infections caused by KPC-producing bacteria is extremely difficult because of their multidrug resistance, which results in high mortality rates. Therapeutic options to treat infections caused by multiresistant Gram-negative bacteria producing KPC-carbapenemases could be used polymyxin B or tigecycline.
Folia Histochemica et Cytobiologica 01/2009; 47(4):537-43. · 1.10 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Resistance to carbapenems is emerging, and it is a great problem to therapeutics. Seven multidrug-resistant (MDR) of Pseudomonas aeruginosa strains were isolated from urine and bronchial specimens. All isolates showed resistance to imipenem and meropenem (MIC; > or =16 mg/L). The resistance to carbapenems in two of seven strains was associated with the production of a metallo-beta-lactamases. Plasmids DNA probes were used to investigate the presence of genes coding for IMP-type enzymes. PCR experiments revealed that bla(IMP) genes were present in two isolates of Pseudomonas aeruginosa (MIC >32 microg/mL for both carbapenems).
Folia Histochemica et Cytobiologica 01/2007; 45(4):405-8. · 1.10 Impact Factor